Introduction
============

Renal cell carcinoma (RCC) comprises 2-3% of all human malignancies and represents the ninth leading cancer in European Union with approximately 84,400 new RCC cases reported in 2012 [@B1]. In the United Sates, a total of 63,990 newly diagnosed RCC cases and 14,400 RCC-related deaths are projected to occur in 2017 [@B2]. Histologically, RCC encompasses a broad spectrum of entities and clear cell RCC (ccRCC) accounts for 70-80% of all RCC cases [@B3], [@B4]. The last few decades have witnessed the substantial developments and advances in both ccRCC understanding and treatment. To date, several histopathological variables, such as tumor-node-metastasis (TNM) stage, Fuhrman nuclear grade, microvascular invasion, and tumor necrosis, have been identified as the independent prognostic factors of ccRCC, and recommended to be applied in routine clinical practice [@B5]. However, the predictive accuracy of the currently-established prognostic systems needs to be improved, as the patients with similar clinical and pathological features could have various outcomes, which highlights the need for novel molecular biomarkers [@B6]-[@B8].

BRCA1 associated protein-1 (BAP1) is a nuclear-localized deubiquitinating enzyme, with ubiquitin carboxyl hydrolase activity and two nuclear localization signal motifs [@B9]. Functionally, BAP1 is a potent tumor suppressor, which could regulate various fundamental cellular processes including proliferation, death, differentiation, gluconeogenesis, and the DNA damage response [@B10], [@B11]. The *BAP1* gene is located on chromosome 3p21.1, a genomic region frequently mutated in a variety of human malignancies including approximately 6-15% ccRCC [@B12]-[@B17]. The *BAP1* mutant ccRCC patients have a worse prognosis than those with wild-type *BAP1* [@B14]-[@B16], and the *BAP1* mutant tumors exhibit a specific gene expression signature [@B13], [@B14], which overall suggests that *BAP1* mutation status could serve as a novel molecular classification parameter of ccRCC.

MicroRNAs (miRNAs) are small non-coding and single-stranded RNAs with about 19-25 nucleotides in length, which regulate a wide array of pathophysiological processes by modulating gene expression through base pairing with the 3\' untranslated region of target mRNAs [@B18], [@B19]. Increased data suggests that miRNAs exert important functions in the development and progression of human malignancies, and could serve as potential biomarkers for the early diagnosis, prognosis prediction, and therapy decision [@B20]-[@B24]. Aberrantly expressed miRNAs between ccRCC tumors and normal kidney tissues have been investigated by various researchers, and different miRNA expression profiles with clinical significance have been identified in ccRCC [@B25]-[@B27]. Recently, a tumor-specific miRNA signature consisting of 22 miRNAs was identified within a cohort of 411 ccRCC patients from The Cancer Genome Atlas (TCGA) project, which could function as an independent prognostic factor of ccRCC [@B28]. However, to date, no study has been conducted to compare the miRNA expression profiles between *BAP1* mutant and wild-type tumors, and no specific miRNA signature was establsished for ccRCC patients with wild-type *BAP1*.

Hence, we stringently designed a stepwise study using the data from TCGA project to: 1) ascertain the differential miRNA expression profiles between wild-type and mutant *BAP1* tumors; 2) identify the miRNAs with prognostic potential from the differential expression profiles; 3) generate a *BAP1* mutation-specific miRNA signature for ccRCC patients with wild-type *BAP1*; and 4) predict target genes and potential involved biological pathways for selected miRNAs.

Materials and Methods
=====================

Patients and samples
--------------------

All subjects in the current study were identified from those who underwent partial nephrectomy or radical nephrectomy for sporadic ccRCC at multiple centers of TCGA consortium, between 1998 and 2010 [@B16]. The full clinical and pathological data were downloaded from the TCGA data portal (January 10^th^, 2017), and re-evaluated according to the predesigned selection criteria: 1) pathologically diagnosed ccRCC; 2) with no history of other malignancies; 3) no chemotherapy or radiation therapy prior to surgery; 4) determined *BAP1* mutation status; and 5) genome-wide miRNA expression profiles analyzed. Furthermore, two experienced urological pathologist (YCZ and XBY) double-checked the pathological TNM stage and Fuhrman nuclear grade according to the 2010 TNM classification of American Joint Committee on Cancer (AJCC) and 2004 World Health Organization criteria, respectively [@B29], [@B30]. Overall, a total of 350 ccRCC patients were included in the present study, with full annotation of the corresponding clinical and pathological parameters such as age, gender, race, AJCC TNM information, Fuhrman grade, surgical types, and detailed follow-up information (**Table [1](#T1){ref-type="table"}**). The study protocol was approved by the institutional review board of Nanjing First Hospital, Nanjing Medical University, informed consent was obtained from all individual participants, and the data collection and procession were performed in accordance with the human subject protection and data access policies of TCGA project.

*BAP1* mutation analysis
------------------------

The whole-exome sequencing data was downloaded from TCGA data portal (January 20^th^, 2017) for the analysis of *BAP1* mutation status, which was acquired on the following two platforms: Illumina HiSeq (Illumina Inc, San Diego, CA, USA) and SOLiD (Applied Biosystems Inc., Foster City, CA, USA), and partially validated on another two sequencing platforms: 454 (Roche, Basel, Switzerland) and Ion Torrent (Life Technologies, Grand Island, NY, USA) [@B16]. Furthermore, the *BAP1* mutation status for each individual was double-checked by applying the online analytical tool: cBioPortal for Cancer Genomics as previously described [@B31].

Microarray data procession
--------------------------

The genome-wide miRNA expression profiling was performed with the Illumina Genome Analyzer and HiSeq platforms (Illumina Inc, San Diego, CA, USA), and presented as reads per million counts (RPM). After downloaded from TCGA data portal (February 2^nd^, 2017), the summary miRNA expression data was processed with BRB-Array tools (version 4.5.1; National Cancer Institute, Bethesda, MD, USA) which were developed by the BRB-Array Tools Development Team [@B32]. In brief, the miRNAs meet the following criteria were retained and log2 transformed for further analysis: 1) more than 1 RPM in at least 10% of all samples, and 2) had changes of more than 1.5 fold from the median value in at least 20% of samples.

Bioinformatics analysis
-----------------------

The miRNA target prediction was conducted using three computational algorithms including TargetScan (version 7.1; <http://www.targetscan.org>) [@B33], miRDB (<http://www.mirdb.org/>) [@B34], and the Good mirSVR score collection within miRanda (<http://www.microrna.org>) [@B35]. The genes predicted by at least two independent tools were uploaded to the Database for Annotation, Visualization and Integrated Discovery (DAVID) program (version 6.8; <https://david.ncifcrf.gov/>) [@B36], [@B37] for further annotation analyses including Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, as we previously reported [@B21].

Statistical analysis
--------------------

The continuous variables were presented as mean ± standard deviation or median and Inter-Quartile Range (IQR), and compared using Student\'s *t*-test or Mann-Whitney U test. The categorical variables were presented as counts and percentages, and compared with Chi-square statistics (or Fisher\'s exact test when appropriate).

The miRNA expression levels between *BAP1* mutant and wild-type tumors were ascertained with Student\'s *t*-test embedded in BRB-Array tools (significance level set as 0.01), and the unsupervised hierarchical cluster analysis was performed by Euclidian distance and average linkage methods. To identify the prognosis-associated miRNAs, the univariate Cox proportional hazards regression analysis was applied, and a risk score formula was developed by combining the expression level (**Expr**) weighted by the regression coefficient (**B**), which was calculated as follows: Risk Score=![](jcav08p2643i001.jpg) [@B23], [@B28]. Survival curves were generated by the Kaplan-Meier method and compared using the log-rank test. The variables identified by the univariate Cox analysis with a threshold *P* value \<0.10 were included in the multivariate Cox proportional hazards regression analysis. The results generated by Cox regression analyses were reported as hazard ratio (HR) and the corresponding 95% confidential interval (CI). The statistical analyses were performed with the use of BRB-Array Tools and SPSS (version 21.0; SPSS Institute Inc, Chicago, IL, USA), and the statistical significance was taken as a two-sided *P* value \<0.05 unless specifically indicated.

Results
=======

Baseline clinical and pathological characteristics
--------------------------------------------------

All 350 participants enrolled in this study were clinically and pathologically diagnosed with ccRCC with no history of other malignancies or neoadjuvant therapy. The median age for all these subjects was 60 years with an IQR of 41-79 years, and the median follow-up time was 33.9 months (IQR: 11.3-55.1 months). Overall, a total of 110 patients (31.4%) died after a median follow-up time of 19.8 months (IQR: 10.3-42.1 months), and the detailed demographic and clinicopathologic characteristics were summarized in **Table [1](#T1){ref-type="table"}**.

*BAP1* mutation status and clinical outcomes
--------------------------------------------

Among all 350 ccRCC patients, a summary of 35 (10.0%) mutations were detected, which included 9 (2.6%) nonsense, 15 (4.3%) missense, 3 (0.8%) splice site, and 8 (2.3%) frameshift mutations (**Figure [1](#F1){ref-type="fig"}** and **[Supplementary Table](#SM0){ref-type="supplementary-material"} S1**). The ccRCC patients with mutated *BAP1* showed a trend towards higher AJCC stage (*P*=0.006), pathologic T stage (*P*=0.009), Fuhrman grade (*P*=0.003) and distant metastasis (*P*=0.029) compared with those with wild-type *BAP1* (**Table [1](#T1){ref-type="table"}**). As depicted in **Figure [1](#F1){ref-type="fig"}**, the patients with *BAP1* mutant tumors had a worse prognosis in terms of median overall survival (OS; *BAP1* mutant vs. wild type: 31.7 vs. 86.7 months; *P*=0.008). Furthermore, the univariate Cox regression analysis confirmed that patients with mutant *BAP1* had a significantly higher probability of death (HR =1.909, 95% CI: 1.175-3.102; *P*=0.009); however, unfortunately, it did not pass the multivariate analysis after adjusting for the other significant prognostic variables (**[Supplementary Table](#SM0){ref-type="supplementary-material"} S2**).

Differentially expressed miRNAs between *BAP1* mutant and wild-type tumors
--------------------------------------------------------------------------

The miRNA expression in *BAP1* mutated (n=35) and wild-type (n=315) tumors was profiled, and a total of 33 miRNAs were found to be expressed differentially after adjustment for multiple testing (**[Supplementary Table](#SM0){ref-type="supplementary-material"} S3**). Among all the 33 miRNAs, 15 miRNAs (45.5%) were up-regulated and the remaining 18 (54.5%) were down-regulated in tumors with mutated *BAP1* compared with those with wild-type *BAP1*. In addition, the unsupervised hierarchical clustering with the 33 miRNAs expression data could clearly separate the tumors with mutated and wild-type *BAP1* (**Figure [2](#F2){ref-type="fig"}**).

Establishment of *BAP1* mutation-specific miRNA signature
---------------------------------------------------------

To identify miRNAs of prognostic values for ccRCC patients with wild-type *BAP1*, the 33 differentially expressed miRNAs were subjected to univariate Cox proportional hazard regression analysis. A total of eleven miRNAs (miR-149, miR-29b-2, miR-182, miR-183, miR-21, miR-365-2, miR-671, miR-365-1, miR-10b, miR-139, and miR-181a-2) were found to be significantly related with patient survival (**[Supplementary Table](#SM0){ref-type="supplementary-material"} S4**), and confirmed by Kaplan-Meier survival curves (**Figure [3](#F3){ref-type="fig"}**). Among the 11 significant miRNAs, eight miRNAs (miR-149, miR-29b-2, miR-182, miR-183, miR-21, miR-365-2, miR-671, and miR-365-1) were negatively associated with patients\' OS and the other three (miR-10b, miR-139, and miR-181a-2) were positively associated. Finally, an eleven-miRNA signature risk score was calculated, and the 315 ccRCC patients with wild-type *BAP1* were divided into high-risk (n= 158) and low-risk (n=157) groups (**Figure [4](#F4){ref-type="fig"}**).

Validation of the eleven-miRNA signature as an independent prognostic factor for ccRCC patients with wild-type *BAP1*
---------------------------------------------------------------------------------------------------------------------

As presented in the Kaplan-Meier survival curves (**Figure [4](#F4){ref-type="fig"}**), the high-risk patients had a shorter median OS compared with the low-risk ones (high- vs. low-risk: 63.7 vs. 91.7 months; *P*\<0.001). The differences in patients\' OS corresponded to a HR of 2.354 (95% CI: 1.514-3.660; *P*\<0.001) derived from the univariate Cox regression analysis. After adjusting for the other significant variables including age, AJCC stage, pathologic T, metastasis status, Fuhrman grade, and surgical type (**Table [2](#T2){ref-type="table"}**), the eleven-miRNA signature was proven as an independent prognostic factor for *BAP1* wild-type ccRCC patients (HR=1.602, 95% CI: 1.012-2.536; *P*=0.044).

Target gene prediction and functional annotation analysis
---------------------------------------------------------

Three computational algorithms (TargentScan, miRDB, and miRanda) were applied to predict miRNA targets, and a total of 2268 target genes were selected for miR-29b-2, 1030 for miR-182, and 1332 for miR-671 by at least two independent tools (**Figure [5](#F5){ref-type="fig"}** and **[Supplementary Table](#SM0){ref-type="supplementary-material"} S5**). The GO enrichment analysis of miRNA target genes identified a summary of 281 terms for miR-29b-2, 337 for miR-182, and 278 for miR-671, which indicated a wide range of biological function during the development and progression of ccRCC (**[Supplementary Table](#SM0){ref-type="supplementary-material"} S5**). Furthermore, the KEGG pathway enrichment analysis demonstrated 32 miR-29b-2 associated, 62 miR-182 related, and 25 miR-671 linked pathways (**[Supplementary Table](#SM0){ref-type="supplementary-material"} S5**). As shown in **Figure [5](#F5){ref-type="fig"}**, the top 10 related pathways for each miRNA suggested that they were widely involved in the cancer-related pathways. Of note, the results provided direct evidence that miR-182 was involved in the pathway "renal cell carcinoma" through modulating eight target genes.

Discussion
==========

The identification and validation of novel biomarkers for ccRCC comprise a significant area of practical cancer research [@B38], [@B39]. The major findings of the present study are as follows: 1) *BAP1* was mutated in about 10.0% of ccRCC patients, and those with mutated *BAP1* had a worse prognosis; 2) thirty-three miRNAs expressed differentially between wild-type and mutated *BAP1* tumors; 3) a *BAP1* mutation-specific miRNA signature consisting of eleven miRNAs could serve as an independent prognostic parameter for ccRCC patients with wild-type *BAP1*. To the best of our knowledge, this is the first study to explore the genome-wide miRNA expression in *BAP1* mutant and wild-type ccRCC tumors, which could help predict patient prognosis in the era of precision medicine.

*BAP1* is a classical two-hit tumor suppressor gene with important functions in cell proliferation and growth inhibition [@B40]. The immunohistochemistry assays of RCC tumor tissues have demonstrated that loss of BAP1 protein expression was specific for ccRCC compared with other histological subtypes of RCC [@B41], [@B42], and could function as a potent prognostic factor for ccRCC [@B43]-[@B45]. In the current study, we observed that *BAP1* was mutated in 10.0% of the 350 ccRCC patients, with the similar frequency as the previous immunohistochemistry [@B41], [@B43], [@B44] and mutational analyses studies [@B12]-[@B17]. The ccRCC patients with mutated *BAP1* were more likely to present high AJCC stage, pathologic T stage, Fuhrman grade and distant metastasis, and had a shorter median OS (*BAP1* mutant vs. wild type: 31.7 vs. 86.7 months; *P*=0.008). In the Cox regression analysis, a HR of 1.909 (95% CI: 1.175-3.102; *P*=0.009) was obtained from the univariate analysis; however, no significant result for the prognostic value of *BAP1* mutation was found after including the other variables for multivariate analysis, which could be explained by the limited sample size. It is conceivable that *BAP1* mutation could serve as a potent prognostic parameter, as previous studies and the current study have indicated that ccRCC patients with mutated *BAP1* had a shorter median survival time [@B14], [@B15], [@B17].

Previous studies have demonstrated that *BAP1* mutant tumors exhibit a highly specific gene expression signature [@B13], [@B14]; however, to date, the miRNA expression profiles between *BAP1* mutant and wild-type tumor have never been compared. As a class of small, endogenous, non-coding RNAs, miRNAs have been suggested to regulate a wide range of pathophysiological processes including carcinogenesis and metastasis [@B19]. In the current study, we explored the genome-wide miRNA expression profiles in *BAP1* mutant and wild-type ccRCC tumors, and found a total of 33 differentially expressed miRNAs. Subsequently, eleven miRNAs (miR-149, miR-29b-2, miR-182, miR-183, miR-21, miR-365-2, miR-671, miR-365-1, miR-10b, miR-139, and miR-181a-2) were confirmed to be of prognostic values for ccRCC patients with wild-type *BAP1*, and a *BAP1* mutation-specific miRNA signature combining all the 11 miRNAs was generated. Among the 11 miRNAs, eight except miR-29b-2, miR-182, and miR-671 were overlapped with the tumor-specific miRNA signature of 22 miRNAs reported by our group [@B28], partially due to the fact that *BAP1* wild-type ccRCC patients accounted for 90.0% of all subjects.

All the three miRNAs (miR-29b-2, miR-182, and miR-671) were risky miRNAs, as the higher expression levels were negatively associated with patient survival. miR-29b-2 is transcribed from a locus at chromosome 1q32.2 with 2268 predicted target genes, and functions as a double-edged sword in the development and progression of human malignancies [@B46], [@B47]. Even though miR-29b-2 was well reputed as a tumor suppressor, the emerging evidence has demonstrated that it could exert oncogenic functions under certain conditions [@B48], [@B49], which was in line with the current study. miR-182 is a member of the miR-183 family, which could function as an tumor promoter in the urologic neoplasms including prostate cancer and bladder cancer [@B50], [@B51]. In this study, a total of 1030 target gene of miR-182 were predicted, and 62 pathways were enriched including "proteoglycans in cancer", "pathway in cancer", "Wnt signaling pathway", "renal cell carcinoma", and others. Contrary to the current study, Xu and colleagues found the down regulation of miR-182 in RCC tissues compared with the matched normal tissues, and demonstrated that miR-182 could suppress the proliferation and carcinogenesis of RCC cell lines by *in vitro* and *in vivo* studies [@B52]. As for miR-671, the biological functions in the development and progression of human cancers remains not yet understood. The bioinformatics analysis identified a total of 1332 target genes and enriched 278 GO terms and 25 pathways including "cell adhesion molecules", \'\'Notch signaling pathway,\'\' \'\'Hippo signaling pathway\'\', et al for miR-671.

Some limitations of the current study should be acknowledged. First, due to the limited follow-up information, the endpoint of the present study was only OS [@B14], which could hinder the yielding of more interesting analyses. Second, in the multivariate Cox regression analysis, *BAP1* mutation was not proved as an independent prognostic factor, which could be partially attributed to the limited sample size. Third, even though we strictly selected the subjects to control the potential heterogeneity and applied the leave-one-out cross validation method, the false positive results do potentially exist, which need an external validation cohort and functional studies to validate the results.

Conclusions
===========

In summary, by employing a large independent ccRCC patient cohort, our study identified a total of 33 miRNAs differentially expressed between *BAP1* mutant and wild-type tumors, and generated a *BAP1* mutation-specific miRNA signature consisting of eleven miRNAs, which could serve as a novel prognostic biomarker for ccRCC patients with wild-type *BAP1*. Further studies focusing on the verifications of our findings in prospectively designed clinical trials, and the functional elucidation of these miRNAs are warranted.
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![***BAP1* mutation status correlates with overall survival.** A. Pie chart representing the distribution of different *BAP1* mutation types in 350 ccRCC patients; B. Kaplan-Meier curve analysis of the association between *BAP1* mutation status and overall survival in 350 ccRCC patients.](jcav08p2643g001){#F1}

![**Unsupervised cluster analysis of the 33 differentially expressed miRNAs between *BAP1* mutant and wild-type tumors.**The transformed log2 intensities of significant miRNAs were mean centered across 350 ccRCC samples and a hierarchical clustering with average linkage was conducted.](jcav08p2643g002){#F2}

![**Kaplan-Meier curve analysis of miRNAs for the overall survival in ccRCC patients with wild-type *BAP1*.** A total of 11 miRNAs were presented, including miR-149, miR-29b-2, miR-182, miR-183, miR-21, miR-365-2, miR-671, miR-365-1, miR-10b, miR-139, and miR-181a-2.](jcav08p2643g003){#F3}

![**The *BAP1* mutation-specific miRNA risk score analysis of ccRCC patients with wild-type *BAP1*.** A. miRNA risk score distribution; B. Patients\' survival status and time; C. Heatmap of the miRNA expression profiles; rows represented miRNAs, and columns indicated patients. The red dotted line represented the miRNA signature cutoff value (median), which divided patients into low-risk and high-risk groups. D. Kaplan-Meier curve analysis of the miRNA signature for the overall survival in 315 ccRCC patients with wild-type *BAP1*.](jcav08p2643g004){#F4}

![**Predicted miRNA target genes and enriched KEGG pathways**. The Venn Diagrams of predicted targets for miR-29b-2 (A), miR-182 (B), and miR-671 (C); the top 10 related KEGG pathway enriched by target genes for miR-29b-2 (D), miR-182 (E), and miR-671 (F).](jcav08p2643g005){#F5}

###### 

Clinical characteristics of patients with clear cell renal cell carcinoma

  ----------------------------------------------------------------------------------------
  Category                Total\        *BAP1* Status   *P* Value^a^                    
                          (n = 350)                                                     
  ----------------------- ------------- --------------- -------------- ---------------- --
  **Age**, Median (IQR)   60 (41, 79)   60 (41, 79)     60 (41,79)     0.464            

  **Ethnicity**                                                        0.450            

  Caucasian               332 (94.9%)   299 (94.9%)     33 (94.3%)                      

  African                 11 (3.1%)     9 (2.9%)        2 (5.7%)                        

  Asian                   7 (2.0%)      7 (2.2%)        0 (0.0%)                        

  **Gender**                                                           **\<0.001^b^**   

  Male                    225 (64.3%)   213 (67.6%)     12 (34.3%)                      

  Female                  125 (35.7%)   102 (32.4%)     23 (65.7%)                      

  **AJCC Stage**                                                       **0.006^b^**     

  Stage Ⅰ                 152 (43.4%)   146 (46.3%)     6(17.1%)                        

  Stage Ⅱ                 36 (10.3%)    31 (9.8%)       5 (14.3%)                       

  Stage Ⅲ                 103 (29.4%)   90 (28.6%)      13 (37.1%)                      

  Stage Ⅳ                 59 (16.9%)    48 (15.2%)      11 (31.4%)                      

  **Tumor Size**                                                       **0.009^b^**     

  T1                      157 (44.9%)   150 (47.6%)     7 (20.0%)                       

  T2                      45 (12.9%)    37 (11.7%)      8 (22.9%)                       

  T3                      143 (40.9%)   123 (39.0%)     20 (57.1%)                      

  T4                      5 (1.4%)      5 (1.6%)        0 (0.0%)                        

  **Lymph Node**                                                       0.088            

  N0                      159 (45.4%)   138 (43.8%)     21 (60.0%)                      

  N1                      11 (3.1%)     9 (2.9%)        2 (5.7%)                        

  NX                      180 (51.4%)   168 (53.3%)     12 (34.3%)                      

  **Metastasis Status**                                                **0.029^b^**     

  M0                      291 (83.1%)   267 (84.8%)     24(68.6%)                       

  M1                      59 (16.9%)    48 (15.2%)      11 (31.4%)                      

  **Fuhrman Grade**                                                    **0.003^b^**     

  G1                      5 (1.4%)      5 (1.6%)        0 (0.0%)                        

  G2                      136 (38.9%)   126 (40.0%)     10 (28.6%)                      

  G3                      150 (42.9%)   137 (43.5%)     13 (37.1%)                      

  G4                      58 (16.6%)    47 (14.9%)      11(31.4%)                       

  GX                      1 (0.3%)      0 (0.0%)        1 (2.9%)                        

  **Surgical Type**                                                    0.648            

  Partial nephrectomy     64 (18.3%)    59 (18.7%)      5 (14.3%)                       

  Radical nephrectomy     286 (81.7%)   256 (81.3%)     30 (85.7%)                      

                                                                                        
  ----------------------------------------------------------------------------------------

*BAP1*, *BRCA1 associated protein-1*; WT, wild-type; MUT, mutant; IQR, Inter-Quartile Range; AJCC, American Joint Committee on Cancer; NX, regional lymph node unknown; GX, Fuhrman Grade unknown.

^a^ *P* values derived from the comparisons between *BAP1* mutant and wild-type groups;

^b^statistical significant results**(in bold).**

###### 

Univariate and multivariate analysis of parameters associated with overall survival in ccRCC patients with wild-type *BAP1*

  Variables                                      HR      95% CI        *P* value
  ---------------------------------------------- ------- ------------- -----------
  **Univariate Cox regression analysis**                               
  Age (≥ 60 vs. \<60)                            2.849   1.772-4.581   \<0.001
  Gender (male vs. female)                       0.949   0.613-1.469   0.815
  Ethnicity (Caucasians vs. non-Caucasians)      1.147   0.362-3.635   0.816
  AJCC stage (Ⅲ+Ⅳ vs. Ⅰ+Ⅱ)                       4.874   3.023-7.857   \<0.001
  Tumor size (T3+T4 vs. T1+T2)                   3.791   2.427-5.922   \<0.001
  Metastasis status (M1 vs. M0)                  4.720   3.074-7.247   \<0.001
  Fuhrman grade (G3+G4 vs. G1+G2)                2.645   1.619-4.319   \<0.001
  Surgical type (RN vs. PN)                      5.131   1.882-13.99   0.001
  Risk Score (High Risk vs. Low Risk)            2.354   1.514-3.660   \<0.001
  **Multivariate Cox regression analysis ^a^**                         
  Age (≥ 60 vs. \<60)                            2.341   1.452-3.775   \<0.001
  AJCC stage (Ⅲ+Ⅳ vs. Ⅰ+Ⅱ)                       2.664   1.529-4.642   0.001
  Metastasis status (M1 vs. M0)                  2.069   1.251-3.420   0.005
  Risk Score (High Risk vs. Low Risk)            1.602   1.012-2.536   0.044

ccRCC, clear cell renal cell carcinoma; *BAP1*, *BRCA1 associated protein-1*; HR, hazard ratio; 95% CI, 95% confidential interval; AJCC, AJCC, American Joint Committee on Cancer; RN, radical nephrectomy; PN, partial nephrectomy.

^a^ The final results after stepwise analysis with Backward (LR) method
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